Avalo Therapeutics Inc
(NAS:AVTX)
$
7
-0.03 (-0.43%)
Market Cap: 73.25 Mil
Enterprise Value: -8.06 Mil
PE Ratio: 0
PB Ratio: 3.22
GF Score: 43/100 Avalo Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023 / 08:35PM GMT
Release Date Price:
$662.4
(+0.36%)
Greg Renza
RBC Capital Markets - Analyst
Welcome back everyone to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotech equity research analysts here at RBC. And we're pleased to be joined by Avalo Therapeutics. Joining from the company is the President and Chief Executive Officer, Dr. Garry Neil.
Garry Neil
Avalo Therapeutics, Inc. - Chairman of the Board & CEO
Hi.
Greg Renza
RBC Capital Markets - Analyst
Hi, Garry.
Garry Neil
Avalo Therapeutics, Inc. - Chairman of the Board & CEO
Great to be here.
Greg Renza
RBC Capital Markets - Analyst
It's great to talk about the company and about the story, especially with really what is an interesting event that's coming up this quarter.
Garry Neil;Greg Renza
Avalo Therapeutics, Inc. - Chairman of the Board & CEO;RBC
That's not the event coming up.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot